Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma 19Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Follicular 12Lymphoma, Non-Hodgkin 11Lymphoma, Mantle-Cell 8Lymphoma, B-Cell, Marginal Zone 6Leukemia, Lymphocytic, Chronic, B-Cell 6Waldenstrom Macroglobulinemia 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large-Cell, Anaplastic 3Burkitt Lymphoma 3Lymphoma, B-Cell 2Leukemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Orbital lymphoma 1Oncology Patients Receiving Chemotherapy 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Immunoproliferative Disorders 1Immune System Diseases 1Graft vs Host Disease 1

Interventions

Dexamethasone 277Lenalidomide 155Bortezomib 152Cyclophosphamide 115Melphalan 107Calcium Dobesilate 107fludarabine phosphate 70carfilzomib 61pomalidomide 55Peripheral Blood Stem Cell Transplantation 53Whole-Body Irradiation 52Mycophenolic Acid 52Granulocyte Colony-Stimulating Factor 52Filgrastim 52daratumumab 46fludarabine 43Tacrolimus 41ixazomib 40Busulfan 40Thalidomide 36Cyclosporine 32dexamethasone acetate 26Stem Cell Transplantation 26Antilymphocyte Serum 25dexamethasone 21-phosphate 22plerixafor 20auricularum 20belantamab mafodotin 19Prednisone 19Etoposide 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Multiple Myeloma × ibritumomab tiuxetan × Clear all
NCT01207765 2017-03-20

Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma

Tufts Medical Center

Phase 2 Terminated
8 enrolled 8 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡